NEPG: The holding subsidiary has obtained approval for drug clinical trials

NEPG announced that its holding subsidiary Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The drug name is DCTY0801 injection, and the indication is for EGFRvIII positive recurrent or progressive high-grade glioma. The approval of this clinical trial is an important milestone in the research and development process of this product, which will accelerate the progress of the company's research products and enhance the company's core competitiveness in the field of cancer treatment